The estimated Net Worth of Lonnie Shoff is at least $1.56 Milione dollars as of 15 March 2016. Lonnie Shoff owns over 3,028 units of Personalis Inc stock worth over $184,450 and over the last 15 years Lonnie sold PSNL stock worth over $1,378,546.
Lonnie has made over 5 trades of the Personalis Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Lonnie sold 3,028 units of PSNL stock worth $509,582 on 15 March 2016.
The largest trade Lonnie's ever made was selling 3,722 units of Personalis Inc stock on 17 March 2014 worth over $443,141. On average, Lonnie trades about 509 units every 50 days since 2009. As of 15 March 2016 Lonnie still owns at least 31,000 units of Personalis Inc stock.
You can see the complete history of Lonnie Shoff stock trades at the bottom of the page.
Lonnie's mailing address filed with the SEC is C/O PERSONALIS, INC., 6600 DUMBARTON CIRCLE, FREMONT, CA, 94555.
Over the last 5 years, insiders at Personalis Inc have traded over $56,423,548 worth of Personalis Inc stock and bought 5,708,990 units worth $54,066,334 . The most active insiders traders include Llp Abingworth, Paul Ricci e Ai, Inc. Tempus. On average, Personalis Inc executives and independent directors trade stock every 15 days with the average trade being worth of $410,996. The most recent stock trade was executed by Ai, Inc. Tempus on 16 August 2024, trading 3,500,000 units of PSNL stock currently worth $17,745,000.
personalis is a genome-scale diagnostics company with a mission to pioneer genome guided medicine. our priority is to obtain the most accurate genetic data from each sample, and then to draw the most reliable medically-focused conclusions from these. our tests are based on whole human genome and exome sequencing, conducted in our state-of-the art laboratory. we analyze results utilizing proprietary databases, advanced human reference sequences, and sophisticated algorithms. personalis genome services provides academic, pharmaceutical, and biotech researchers an accurate and comprehensive end-to-end human genome sequencing and analysis solution. our services support researchers engaging in large case-control and family-based genome studies of complex or mendelian diseases and traits, pharmacogenomics, and cancer.
Personalis Inc executives and other stock owners filed with the SEC include: